The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for a 2017 Times Higher Education (THE) Award in the ‘International Collaboration of the Year’ category.

Combining patient data from visceral leishmaniasis (VL) clinical trials would give scientists and clinicians more tools to understand and treat the disease which can be fatal if untreated.

The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for a 2017 Times Higher Education (THE) Award in the ‘International Collaboration of the Year’ category.

Dihydroartemisinin-piperaquine (DP), a widely used and effective treatment for falciparum malaria, is safe and unlikely to cause severe drug-induced heart problems, a recently published study has found.

Before becoming Project Coordinator for a Mahidol Oxford Tropical Medicine Research Unit, Bangkok–based project tracking antimalarial resistance in the Greater Mekong Subregion, Dr Suttipat Srisutham spent three months at WWARN last year during his PhD studies, learning the basics of the data sharin...

Laboratories participating in WWARN’s globally accredited Proficiency Testing (PT) Programme say the free service provides a check on their activities that helps ensure both the accuracy of findings and the integrity of the research process.

Last year we announced the launch of the Infectious Diseases Data Observatory (IDDO). Members of the IDDO Board met recently to discuss key activities to date and the future direction of the new organisation.

The World Health Assembly has agreed new terminology that aims to establish a common understanding of key terms used to describe poor quality medical products.

Shedding new light on the challenge of measuring malaria medicine quality in sub-Saharan Africa, a new study from 8 countries has found a large and potentially growing market for non-quality-assured (QA) malaria treatments -- medicines not pre-approved by global health organisations – as much as 20%...

New study recommends that primaquine should be included in treatment guidelines against vivax malaria to decrease relapse rates

A pioneering academic conference will bring together, for the first time, people from all over the world dealing with the problem of poor quality medicines and their impact on public health.

Dr Clifford Banda has joined the WWARN team on a TDR, Special Programme for Research and Training in Tropical Diseases, Clinical Research and Development Fellowship. If you work in clinical trials, participate in Clifford’s survey.

TDR, the Special Programme for Research and Training in Tropical Diseases, have convened an independent Data Access Committee to support WWARN data contributors in making decisions on access to malaria datasets.

The Malaria in Pregnancy Scientific Group, a collaboration between WWARN and the Malaria in Pregnancy (MiP) Consortium, has updated the SP Molecular Surveyor, in order to display the most recently published evidence (2014-2016) on the prevalence of common molecular markers of resistance to sulphadox...

The Vivax Surveyor was recently featured in the International Journal for Parasitology: Drugs and Drug Resistance in an article entitled ‘The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials’.

The Institut Pasteur in Cambodia, with support from WWARN, has developed a procedure to help identify P. falciparum susceptibility to piperaquine more effectively in the laboratory.

To mark this year’s World Malaria Day, the WWARN and IDDO team will attend events in the UK to encourage continued discussion on antimalarial resistance in efforts to eliminate the disease.

The Clinical Data Interchange Standards Consortium (CDISC) and the WorldWide Antimalarial Resistance Network (WWARN) are pleased to announce the availability of CDISC Malaria Therapeutic Area (TA) User Guide v1.0, the very first global malaria data standard that enables data capture and assessment f...

The Asia Malaria Images project and exhibition aims to portray those affected most by malaria living in rural settings through photography.

The third Quality of Medical Products and Public Health course will take place in Boston, USA this year, from 10-14 July. The course is a pioneering initiative developed by the London School of Hygiene & Tropical Medicine and the University of Oxford.